Secura Bio

Secura Bio

NV - Las Vegas
Biotechnology
WebsiteLinkedInCareers Page

Focus: Acquisition & Worldwide Commercialization

Secura Bio is a life sciences company focused on Acquisition & Worldwide Commercialization.

Oncology
Funding Stage
PUBLIC
Open Jobs
1

Products & Portfolio (1)

1 discontinued product not shown

COPIKTRA
duvelisib
Peak
SMORAL · CAPSULE
PI3K with inhibitory activity predominantly against PI3K-δ and PI3K-γ isoforms expressed in normal and malignant B-cells. Duvelisib induced growth inhibition and reduced viability in cell lines derived from malignant B-cells and in primary CLL tumor cells. Duvelisib inhibits several key cell-signaling pathways, including B-cell receptor signaling and CXCR12-mediated chemotaxis of malignant B-cells. Additionally, duvelisib inhibits CXCL12-induced T cell migration and M-CSF and IL-4 driven M2 polarization of macrophages.
refractory chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL) after at least two prior lines lines of systemic therapylymphoma+1 more
2018
0

Pipeline & Clinical Trials

Phase 1
Phase 1
Clinical Trials (1)
NCT07001384A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)
Phase 1
Phase 1
Clinical Trials (1)
NCT05065866Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
Phase 1
Phase 1
Clinical Trials (1)
NCT01245179Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
Phase 1
Phase 1
Phase 1/2
Clinical Trials (1)
NCT03534323Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT02158091A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL
Phase 1/2
Phase 1/2
Panobinostat
Rhabdoid Tumor
Phase 2
Clinical Trials (1)
NCT04897880A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT
Phase 2
Phase 2
Clinical Trials (1)
NCT05057247Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC
Phase 2

Open Jobs (1)

Associate Director, Health Economics & Outcomes Research

Remote
Medical Affairs
4d ago
Interview Prep Quick Facts
Founded: 2019
Portfolio: 2 approved products, 7 clinical trials
Top TAs: Oncology
Open Roles: 1 active job
Portfolio Health
Peak1 (50%)
LOE Approaching1 (50%)
2 total products
Therapeutic Area Focus
Oncology
1 marketed
Marketed
Pipeline

Hiring Trend

Stable
1
Open Roles
+1
Added
-1
Filled/Removed

Based on last 4 crawl cycles